Radionuclide therapy in neuroendocrine tumors

European Journal of Endocrinology

Volumn 172, Issue 1, 2015, Pages R1-R8

  Van Der Zwan, Wouter A ^a   Bodei, Lisa ^b   Mueller Brand, Jan ^c   De Herder, Wouter W ^a   Kvols, Larry K ^d   Kwekkeboom, Dik J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DOTATOC Y 90; FLUOROURACIL; OCTREOTATE LU 177; OCTREOTATE[3 TYROSINE]TETRAXETAN LU 177; OCTREOTIDE[3 TYROSINE]TETRAXETAN Y 90; PENTETREOTIDE IN 111; RADIOISOTOPE; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; RADIOPHARMACEUTICAL AGENT; RECEPTOR;

ANGINA PECTORIS; BLOOD TOXICITY; CANCER RADIOTHERAPY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; END STAGE LIVER DISEASE; FATIGUE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HAIR LOSS; HUMAN; KIDNEY FAILURE; MALE INFERTILITY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NONHUMAN; OVERALL SURVIVAL; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; VOMITING; ANIMAL; INTESTINAL NEOPLASMS; MORTALITY; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; STOMACH NEOPLASMS; SURVIVAL RATE; TRENDS;

ANIMALS; HUMANS; INTESTINAL NEOPLASMS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECEPTORS, PEPTIDE; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 84920392196     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0488     Document Type: Review

References (43)

1. 3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Seminars in Nuclear Medicine 2006 36 147-156. (doi:10.1053/j.semnuclmed.2006.01.001)
2. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. Journal of Clinical Oncology 2010 28 1652-1659. (doi:10.1200/JCO.2009.22.8585)
3. Pfeifer AK, Gregersen T, Gronbaek H., Hansen CP, Muller-Brand J, Herskind Bruun K, Krogh K, Kjaer A & Knigge U. Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology 2011 93 189-196. (doi:10.1159/000324096)
4. Cwikla JB, Sankowski A, Seklecka N., Buscombe JR, Nasierowska-Guttmejer A, Jeziorski KG, Mikolajczak R, Pawlak D., Stepien K & Walecki J. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. Annals of Oncology 2010 21 787-794. (doi:10.1093/annonc/mdp372)
5. 3]octreotate: toxicity, efficacy, and survival. Journal of Clinical Oncology 2008 26 2124-2130. (doi:10.1200/JCO.2007.15.2553)
6. Valkema R, De Jong M, Bakker WH, Breeman W.A., Kooij PP, Lugtenburg PJ, De Jong FH, Christiansen A, Kam BL, De Herder WW et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Seminars in Nuclear Medicine 2002 32 110-122. (doi:10.1053/snuc/2002.31025)
7. Anthony LB, Woltering EA, Espenan G.D., Cronin MD, Maloney TJ & McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Seminars in Nuclear Medicine 2002 32 123-132. (doi:10.1053/snuc.2002.31769)
8. 90Y-DOTA]-TOC in metastasized neuroendocrine cancers. Journal of Clinical Oncology 2011 29 2416-2423. (doi:10.1200/JCO.2010. 33.7873)
9. Reubi JC, Schar JC, Waser B, Wenger S., Heppeler A, Schmitt JS & Macke HR. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. European Journal of Nuclear Medicine 2000 27 273-282. (doi:10.1007/s002590050034)
10. Bodei L, Cremonesi M, Grana C.M., Fazio N., Iodice S, Baio SM, Bartolomei M, Lombardo D., Ferrari ME, Sansovini M et al. Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II study. European Journal of Nuclear Medicine and Molecular Imaging 2011 38 2125-2135. (doi:10.1007/s00259-011-1902-1)
11. Ezziddin S, Khalaf F, Vanezi M., Haslerud T, Mayer K, Al Zreiqat A, Willinek W, Biersack HJ & Sabet A. Outcome of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 2014 41 925-933. (doi:10.1007/s00259-013-2677-3)
12. 3]octreotate. Journal of Nuclear Medicine 2011 52 1361-1368. (doi:10.2967/jnumed.111.087932)
13. 90Y-DOTATOC in association with amino acid infusion: a phase I study. European Journal of Nuclear Medicine and Molecular Imaging 2003 30 207-216. (doi:10.1007/s00259-002-1023-y)
14. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Annals of Oncology 2001 12 941-945. (doi:10.1023/A:1011160913619)
15. Waldherr C, Pless M, Maecke H.R., Schumacher T., Crazzolara A, Nitzsche EU, Haldemann A & Mueller-Brand J. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. Journal of Nuclear Medicine 2002 43 610-616.
16. 90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clinical Cancer Research 2007 13 6696-6702. (doi:10.1158/1078-0432.CCR-07-0935)
17. Valkema R, Pauwels SA, Kvols L.K., Kwekkeboom DJ, Jamar F, de Jong M, Barone R, Walrand S., Kooij PP, Bakker WH et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. Journal of Nuclear Medicine 2005 46 (Suppl 1) 83S-91S.
18. 177Lu-DOTATATE: the role of associated risk factors. European Journal of Nuclear Medicine and Molecular Imaging 2008 35 1847-1856. (doi:10.1007/s00259-008-0778-1)
19. Otte A, Herrmann R, Heppeler A., Behe M, Jermann E, Powell P., Maecke HR & Muller J. Yttrium-90 DOTATOC: first clinical results. European Journal of Nuclear Medicine 1999 26 1439-1447. (doi:10.1007/s002590050476)
20. 90Y-labeled somatostatin analogs. Journal of Nuclear Medicine 2005 46 (Suppl 1) 13S-17S.
21. 177Lu-DOTATATE - What is better for therapy? Journal of Nuclear Medicine 2009 50 (Suppl 2) 106 (abstract).
22. Seregni E, Maccauro M, Coliva A., Castellani MR, Bajetta E, Aliberti G, Vellani C., Chiesa C, Martinetti A, Bogni A et al. Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Quarterly Journal of Nuclear Medicine and Molecular Imaging 2010 54 84-91.
23. Villard L, Romer A, Marincek N., Brunner P, Koller MT, Schindler C, Ng Q.K., Macke HR, Muller-Brand J, Rochlitz C et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. Journal of Clinical Oncology 2012 30 1100-1106. (doi:10.1200/JCO.2011.37.2151)
24. 90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. European Journal of Nuclear Medicine and Molecular Imaging 2014 41 223-230. (doi:10.1007/s00259-013-2578-5)
25. Kratochwil C, Giesel FL, Lopez-Benitez R, Schimpfky N., Kunze K, Eisenhut M, Kauczor HU & Haberkorn U. Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clinical Cancer Research 2010 16 2899-2905. (doi:10.1158/1078-0432.CCR-10-0004)
26. 111In-DTPA-octreotide by loco regional administration. European Journal of Nuclear Medicine and Molecular Imaging 2009 36 (Suppl 2) S427 (abstract).
27. Limouris GS, Chatziioannou A, Kontogeorgakos D., Mourikis D, Lyra M, Dimitriou P., Stavraka A, Gouliamos A & Vlahos L. Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases. European Journal of Nuclear Medicine and Molecular Imaging 2008 35 1827-1837. (doi:10.1007/s00259-008-0779-0)
28. Kratochwil C, Giesel FL, Morgenstern A, Bruchertseifer F., Mier W, Zechmann C, Apostolidis C & Haberkorn U. Regional 213Bi-DOTATOC peptide receptor alpha-therapy in patients with neuroendocrine liver metastases refractory to beta-radiation. Journal of Nuclear Medicine 2011 52 (Suppl 1) 1-29 (abstract).
29. 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 2008 35 743-748. (doi:10.1007/s00259-007-0688-7)
30. 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 2011 38 302-311. (doi:10.1007/s00259-010-1631-x)
31. 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmuno-therapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clinical Cancer Research 2003 9 5842-5852.
32. Kong G, Johnston V, Ramdave S., Lau E, Rischin D & Hicks RJ. High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience. Cancer Biotherapy & Radiopharmaceuticals 2009 24 527-533. (doi:10.1089/cbr.2009.0644)
33. Kaemmerer D, Prasad V, Daffner W., Horsch D, Kloppel G, Hommann M & Baum RP. Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World Journal of Gastroenterology 2009 15 5867-5870. (doi:10.3748/wjg.15.5867)
34. 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbeck's Archives of Surgery 2010 395 185-192. (doi:10.1007/s00423-009-0520-x)
35. 3]octreotate in a rat liver micro-metastases model. International Journal of Cancer 2003 104 376-379. (doi:10.1002/ijc.10952)
36. van Essen M., Krenning EP, Kam B.L., de Herder WW, Feelders RA & Kwekkeboom DJ. Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. Journal of Nuclear Medicine 2010 51 383-390. (doi:10.2967/jnumed.109. 068957)
37. 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 2014 41 205-210. (doi:10.1007/s00259-013-2547-z)
38. Raymond E, Dahan L, Raoul J.L., Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P., Smith D, Vinik A et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine 2011 364 501-513. (doi:10.1056/NEJMoa1003825)
39. Yao JC, Shah MH, Ito T, Bohas C.L., Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J., de Vries EG et al. Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine 2011 364 514-523. (doi:10.1056/NEJMoa1009290)
40. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy. Journal of Nuclear Medicine 2012 53 1663-1669. (doi:10.2967/jnumed. 112.107482)
41. 90Yttrium-DOTA-TOC in neuroendocrine tumors? European Journal of Nuclear Medicine and Molecular Imaging 2002 29 (Suppl 1) S100 (abstract).
42. 3]-octreotate treatment in patients with disseminated gastroenter-opancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney. World Journal of Surgery 2010 34 1368-1372. (doi:10.1007/s00268-009-0387-6)
43. 3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer 2010 116 1084-1092. (doi:10.1002/cncr.24796)